Board of Directors

Thomas_King.png

THOMAS B. KING

Thomas B. King has served as a director of the Company since 2017. Mr. King brings a wealth of knowledge from nearly 40 years experience in biopharma leadership positions ranging from large to development-stage companies. Mr. King has built, operated and sold multiple public specialty pharmaceutical businesses, including most recently serving as interim CEO for VIVUS, Inc. (Nasdaq: VVUS), from December 2017 to April 2018.

Prior to that, Mr. King was at Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), where he served as President, Chief Executive Officer and a member of the board of directors from June 2003 until its sale in July 2016. From September 2002 to April 2003, he served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately-held biopharmaceutical development-stage company. From
January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation (Nasdaq: NSTA), including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly-traded biopharmaceutical company.

Mr. King currently serves on the board of directors of VIVUS, Inc., a publicly-traded biopharmaceutical company, and Faraday Pharmaceuticals, Inc., and Satsuma Pharmaceuticals, Inc., both privately-held biotechnology companies. Mr. King also serves as a mentor at SPIRE Bioventures, a multi-disciplinary consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute.

Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.


John_Donovan.jpg

JOHN DONOVAN, MD MBA

John Donovan is a board certified anesthesiologist with 25 years of experience in clinical medicine and 14 years of experience working with life science companies  Dr. Donovan has held a number of senior business development positions for anesthesia/pain biotechs, including Signature Therapeutics and Anesiva (NASDAQ: ANSV).

Previously, Dr. Donovan built and ran a large anesthesiology medical practice, East Bay Anesthesiology Medical Group, which provides anesthesia and perioperative medical services to hospitals in the Sutter Health system. Dr. Donovan has conducted research and published on postsurgical pain management, including the use of continuous peripheral nerve blocks for TKA, and has also served as an advisor to a variety of emerging life science businesses. Dr. Donovan completed his residency in anesthesiology at the University of California San Francisco where he was chief resident and continues to maintain an active faculty appointment. He served as  a diving medical officer in the U.S. Navy and has been involved with global health efforts in Haiti since the 2010 earthquake.

Dr. Donovan earned BS and MD degrees from Georgetown University and an MBA from the Haas School of Business at the University of California Berkeley.


Frank_Bellizzi.png

FRANK J. BELLIZZI, DMD

Frank Bellizzi has over 25 years of experience, within and beyond Life Sciences, as an operator, consultant and advisor leading business transformation and growth. Immediately prior to co-founding Concentric, Dr. Bellizzi was CEO of HydraDx, a saliva-based platform for real time health monitoring using a connected device. Dr. Bellizzi also served as President of Zila Pharmaceuticals (NASDAQ: ZILA) where he successfully created and implemented a strategy to build an oral cancer detection business, growing its flagship product, ViziLite® Plus, into the leading oral cancer detection test in the U.S. and internationally.

In addition, as Chief Financial Officer and Chief Operating Officer of Streampipe, a rich media software company, Dr. Bellizzi engineered all aspects of the company’s growth and successful sale to Loudeye (NASDAQ: LOUD).

Earlier in his career, as a member of Booz, Allen & Hamilton’s Health Industries Practice, Dr. Bellizzi facilitated a number of high-profile engagements, including the merger and integration of two leading West Coast health systems, the acquisition strategy for a leading New York health system, and the operational revitalization of the Australian health care system.

Dr. Bellizzi earned his MBA from the Wharton School of the University of Pennsylvania, his DMD from the University of Pennsylvania School of Dental Medicine, and his BS from Georgetown University.